Literature DB >> 9042648

Variation in nebulizer aerosol output and weight output from the Mefar dosimeter: implications for multicentre studies.

S Chinn1, W A Arossa, D L Jarvis, C M Luczynska, P G Burney.   

Abstract

The active aerosol component of nebulizers is less than 100% of output by weight, and may vary between nebulizers in different batches from the same manufacturer. A measure of bronchial responsiveness to methacholine, which can overcome this problem, is required. One hundred and sixty nebulizers from 21 centres in the European Community Respiratory Health Survey (ECRHS) were calibrated for aerosol and weight output. Methacholine challenge data were obtained for 1,021 subjects in three English centres of the ECRHS. The dose producing a 20% fall in forced expiratory volume in one second (PD20), and log-slope, the regression slope of percentage decline in FEV1 with log (dose), were calculated, with and without calibration of nebulizers by weight. Within-centre variation in nebulizer percentage aerosol output had a coefficient of variation of less than 10%. Unlike PD20, log-slope is unaffected by constant percentage overestimation of nebulizer output. Variation in output by weight of nebulizers of 10% had little affect on log-slope. It is, however, affected by the scheduled range of doses. Log-slope shows advantages in analysis, and is less affected by variation in nebulizer output. It can be used for multicentre comparisons, with restriction to a common dose protocol.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9042648     DOI: 10.1183/09031936.97.10020452

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

Review 1.  Methodology of bronchial responsiveness.

Authors:  S Chinn
Journal:  Thorax       Date:  1998-11       Impact factor: 9.139

Review 2.  Cough challenge in the assessment of cough reflex.

Authors:  A H Morice; J A Kastelik; R Thompson
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

3.  Alternaria sensitisation at age 6 years is associated with subsequent airway hyper-responsiveness in non-asthmatics.

Authors:  Anunya Hiranrattana; Debra A Stern; Stefano Guerra; Marilyn Halonen; Anne L Wright; Michael Daines; Fernando D Martinez; Wayne J Morgan
Journal:  Thorax       Date:  2018-03-21       Impact factor: 9.139

4.  Relation of bronchial responsiveness to body mass index in the ECRHS. European Community Respiratory Health Survey.

Authors:  S Chinn; D Jarvis; P Burney
Journal:  Thorax       Date:  2002-12       Impact factor: 9.139

5.  Individual allergens as risk factors for bronchial responsiveness in young adults.

Authors:  S Chinn; D Jarvis; C Luczynska; P Burney
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

6.  Maternal late-pregnancy serum 25-hydroxyvitamin D in relation to childhood wheeze and atopic outcomes.

Authors:  Katharine C Pike; Hazel M Inskip; Sian Robinson; Jane S Lucas; Cyrus Cooper; Nicholas C Harvey; Keith M Godfrey; Graham Roberts
Journal:  Thorax       Date:  2012-06-15       Impact factor: 9.139

7.  Interaction between gas cooking and GSTM1 null genotype in bronchial responsiveness: results from the European Community Respiratory Health Survey.

Authors:  André F S Amaral; Adaikalavan Ramasamy; Francesc Castro-Giner; Cosetta Minelli; Simone Accordini; Inga-Cecilie Sørheim; Isabelle Pin; Manolis Kogevinas; Rain Jõgi; David J Balding; Dan Norbäck; Giuseppe Verlato; Mario Olivieri; Nicole Probst-Hensch; Christer Janson; Jan-Paul Zock; Joachim Heinrich; Deborah L Jarvis
Journal:  Thorax       Date:  2014-03-10       Impact factor: 9.139

8.  Prenatal development is linked to bronchial reactivity: epidemiological and animal model evidence.

Authors:  Katharine C Pike; Shelley A Davis; Samuel A Collins; Jane S A Lucas; Hazel M Inskip; Susan J Wilson; Elin R Thomas; Harris A Wain; Piia H M Keskiväli-Bond; Cyrus Cooper; Keith M Godfrey; Christopher Torrens; Graham Roberts; John W Holloway
Journal:  Sci Rep       Date:  2014-04-17       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.